Veterinary Vaccine Adjuvants Market By Type , By Route of Administration By Type of Animal : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

Veterinary Vaccine Adjuvants Market

The veterinary vaccine adjuvants market was valued at $0.4 billion in 2023 and is projected to reach $0.6 billion by 2033, growing at a CAGR of 4.6% from 2024 to 2033.

A veterinary vaccine adjuvant is an element essential to enhance the immune response of the administered vaccine in animals. An adjuvant is a bioactive compound that upon addition elevates the immune response generated by vaccines. The mechanism of action of adjuvants involves enhancement in the antigen presentation process or modulation of immune pathways through the stimulation of certain receptors. The most common forms of adjuvants included in veterinary vaccines are oil emulsions, aluminum salts, liposomes, bacterial derivatives, and saponins.

Increase in the trend of petkeeping and surge in expenditure on their health are the key drivers of the veterinary vaccine adjuvants market. Moreover, the prevalence of diseases in animals has upsurged over the past few years, thereby boosting the demand for veterinary vaccine adjuvants. In recent times, the addition of nanoparticle-based adjuvants in vaccines is trending in the market as they offer controlled release and encapsulate the antigens, thus preventing their degradation. Furthermore, microparticle-based and genetic adjuvants are acquiring prominent traction owing to their highly targeted action mechanism.

However, several adjuvants potentially cause severe systemic reactions and local reactogenicity in animals, raising concerns pertaining to their safety and hampering the development of the market. In addition, advancements in vaccine development are eliminating the requirement of adjuvants, without limiting the efficacy of vaccines. Such innovations are anticipated to restrain the development of the market in upcoming years. Despite the innovations in vaccine formation, several gaps exist in the generation of effective immune response, such as pathogen variability and virulent reversion of vaccine strains. These shortcomings present lucrative opportunities for the players in the veterinary vaccine adjuvant market. Further, the implementation of different veterinary vaccination drives by governments, such as the foot and mouth disease vaccination program by the Department of Animal Husbandry & Dairying in India, open new avenues for market expansion.

Segment Review

The veterinary vaccine adjuvants market is segmented into type, route of administration, type of animal, and region. On the basis of type, the market is divided into alum & calcium salts, oil emulsion adjuvants, liposomes & archaeosomes, nanoparticles & microparticles, and others. By route of administration, it is classified into oral, subcutaneous, intramuscular, and others. As per type of animal, it is bifurcated into livestock animals and companion animals. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the alum & calcium salts segment dominated the market in 2023.

By route of administration, the intramuscular segment accounted for a high market share in 2023.

As per type of animal, the livestock animals segment was the highest shareholder in 2023.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The leading players operating in the global veterinary vaccine adjuvants market include SEPPIC, SPI Pharma, Inc., Bioveta AS, Croda Internation PLC, Merck & Co., Inc., MVP Laboratories, OZ Biosciences, InvivoGen Corporation., Evonik Industries AG, and Zoetis, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

Alum and Calcium Salts
Oil Emulsion Adjuvants
Liposomes and Archaeosomes
Nanoparticles and Microparticles
Others

By Route Of Administration

Oral
Subcutaneous
Intramuscular
Others

By Type Of Animal

Livestock Animals
Companion Animals

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

SEPPIC
SPI Pharma, Inc.
Bioveta AS
Croda Internation PLC
Merck & Co., Inc.
MVP Laboratories
OZ Biosciences
InvivoGen Corporation.
Evonik Industries AG
Zoetis, Inc.

Product Code: A324537

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Type
4.2. Alum And Calcium Salts
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Oil Emulsion Adjuvants
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
4.4. Liposomes And Archaeosomes
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
4.5. Nanoparticles And Microparticles
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country
4.6. Others
- 4.6.1. Key Market Trends, Growth Factors and Opportunities
- 4.6.2. Market Size and Forecast, By Region
- 4.6.3. Market Share Analysis, By Country

CHAPTER 5: VETERINARY VACCINE ADJUVANTS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Route of Administration
5.2. Oral
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Subcutaneous
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
5.4. Intramuscular
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
5.5. Others
- 5.5.1. Key Market Trends, Growth Factors and Opportunities
- 5.5.2. Market Size and Forecast, By Region
- 5.5.3. Market Share Analysis, By Country

CHAPTER 6: VETERINARY VACCINE ADJUVANTS MARKET, BY TYPE OF ANIMAL

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Type of Animal
6.2. Livestock Animals
- 6.2.1. Key Market Trends, Growth Factors and Opportunities
- 6.2.2. Market Size and Forecast, By Region
- 6.2.3. Market Share Analysis, By Country
6.3. Companion Animals
- 6.3.1. Key Market Trends, Growth Factors and Opportunities
- 6.3.2. Market Size and Forecast, By Region
- 6.3.3. Market Share Analysis, By Country

CHAPTER 7: VETERINARY VACCINE ADJUVANTS MARKET, BY REGION

7.1. Market Overview
- 7.1.1 Market Size and Forecast, By Region
7.2. North America
- 7.2.1. Key Market Trends and Opportunities
- 7.2.2. Market Size and Forecast, By Type
- 7.2.3. Market Size and Forecast, By Route of Administration
- 7.2.4. Market Size and Forecast, By Type of Animal
- 7.2.5. Market Size and Forecast, By Country
- 7.2.6. U.S. Veterinary Vaccine Adjuvants Market
  - 7.2.6.1. Market Size and Forecast, By Type
  - 7.2.6.2. Market Size and Forecast, By Route of Administration
  - 7.2.6.3. Market Size and Forecast, By Type of Animal
- 7.2.7. Canada Veterinary Vaccine Adjuvants Market
  - 7.2.7.1. Market Size and Forecast, By Type
  - 7.2.7.2. Market Size and Forecast, By Route of Administration
  - 7.2.7.3. Market Size and Forecast, By Type of Animal
- 7.2.8. Mexico Veterinary Vaccine Adjuvants Market
  - 7.2.8.1. Market Size and Forecast, By Type
  - 7.2.8.2. Market Size and Forecast, By Route of Administration
  - 7.2.8.3. Market Size and Forecast, By Type of Animal
7.3. Europe
- 7.3.1. Key Market Trends and Opportunities
- 7.3.2. Market Size and Forecast, By Type
- 7.3.3. Market Size and Forecast, By Route of Administration
- 7.3.4. Market Size and Forecast, By Type of Animal
- 7.3.5. Market Size and Forecast, By Country
- 7.3.6. Germany Veterinary Vaccine Adjuvants Market
  - 7.3.6.1. Market Size and Forecast, By Type
  - 7.3.6.2. Market Size and Forecast, By Route of Administration
  - 7.3.6.3. Market Size and Forecast, By Type of Animal
- 7.3.7. France Veterinary Vaccine Adjuvants Market
  - 7.3.7.1. Market Size and Forecast, By Type
  - 7.3.7.2. Market Size and Forecast, By Route of Administration
  - 7.3.7.3. Market Size and Forecast, By Type of Animal
- 7.3.8. UK Veterinary Vaccine Adjuvants Market
  - 7.3.8.1. Market Size and Forecast, By Type
  - 7.3.8.2. Market Size and Forecast, By Route of Administration
  - 7.3.8.3. Market Size and Forecast, By Type of Animal
- 7.3.9. Italy Veterinary Vaccine Adjuvants Market
  - 7.3.9.1. Market Size and Forecast, By Type
  - 7.3.9.2. Market Size and Forecast, By Route of Administration
  - 7.3.9.3. Market Size and Forecast, By Type of Animal
- 7.3.10. Spain Veterinary Vaccine Adjuvants Market
  - 7.3.10.1. Market Size and Forecast, By Type
  - 7.3.10.2. Market Size and Forecast, By Route of Administration
  - 7.3.10.3. Market Size and Forecast, By Type of Animal
- 7.3.11. Rest of Europe Veterinary Vaccine Adjuvants Market
  - 7.3.11.1. Market Size and Forecast, By Type
  - 7.3.11.2. Market Size and Forecast, By Route of Administration
  - 7.3.11.3. Market Size and Forecast, By Type of Animal
7.4. Asia-Pacific
- 7.4.1. Key Market Trends and Opportunities
- 7.4.2. Market Size and Forecast, By Type
- 7.4.3. Market Size and Forecast, By Route of Administration
- 7.4.4. Market Size and Forecast, By Type of Animal
- 7.4.5. Market Size and Forecast, By Country
- 7.4.6. Japan Veterinary Vaccine Adjuvants Market
  - 7.4.6.1. Market Size and Forecast, By Type
  - 7.4.6.2. Market Size and Forecast, By Route of Administration
  - 7.4.6.3. Market Size and Forecast, By Type of Animal
- 7.4.7. China Veterinary Vaccine Adjuvants Market
  - 7.4.7.1. Market Size and Forecast, By Type
  - 7.4.7.2. Market Size and Forecast, By Route of Administration
  - 7.4.7.3. Market Size and Forecast, By Type of Animal
- 7.4.8. Australia Veterinary Vaccine Adjuvants Market
  - 7.4.8.1. Market Size and Forecast, By Type
  - 7.4.8.2. Market Size and Forecast, By Route of Administration
  - 7.4.8.3. Market Size and Forecast, By Type of Animal
- 7.4.9. India Veterinary Vaccine Adjuvants Market
  - 7.4.9.1. Market Size and Forecast, By Type
  - 7.4.9.2. Market Size and Forecast, By Route of Administration
  - 7.4.9.3. Market Size and Forecast, By Type of Animal
- 7.4.10. South Korea Veterinary Vaccine Adjuvants Market
  - 7.4.10.1. Market Size and Forecast, By Type
  - 7.4.10.2. Market Size and Forecast, By Route of Administration
  - 7.4.10.3. Market Size and Forecast, By Type of Animal
- 7.4.11. Rest of Asia-Pacific Veterinary Vaccine Adjuvants Market
  - 7.4.11.1. Market Size and Forecast, By Type
  - 7.4.11.2. Market Size and Forecast, By Route of Administration
  - 7.4.11.3. Market Size and Forecast, By Type of Animal
7.5. LAMEA
- 7.5.1. Key Market Trends and Opportunities
- 7.5.2. Market Size and Forecast, By Type
- 7.5.3. Market Size and Forecast, By Route of Administration
- 7.5.4. Market Size and Forecast, By Type of Animal
- 7.5.5. Market Size and Forecast, By Country
- 7.5.6. Brazil Veterinary Vaccine Adjuvants Market
  - 7.5.6.1. Market Size and Forecast, By Type
  - 7.5.6.2. Market Size and Forecast, By Route of Administration
  - 7.5.6.3. Market Size and Forecast, By Type of Animal
- 7.5.7. Saudi Arabia Veterinary Vaccine Adjuvants Market
  - 7.5.7.1. Market Size and Forecast, By Type
  - 7.5.7.2. Market Size and Forecast, By Route of Administration
  - 7.5.7.3. Market Size and Forecast, By Type of Animal
- 7.5.8. South Africa Veterinary Vaccine Adjuvants Market
  - 7.5.8.1. Market Size and Forecast, By Type
  - 7.5.8.2. Market Size and Forecast, By Route of Administration
  - 7.5.8.3. Market Size and Forecast, By Type of Animal
- 7.5.9. Rest of LAMEA Veterinary Vaccine Adjuvants Market
  - 7.5.9.1. Market Size and Forecast, By Type
  - 7.5.9.2. Market Size and Forecast, By Route of Administration
  - 7.5.9.3. Market Size and Forecast, By Type of Animal

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

9.1. SEPPIC
- 9.1.1. Company Overview
- 9.1.2. Key Executives
- 9.1.3. Company Snapshot
- 9.1.4. Operating Business Segments
- 9.1.5. Product Portfolio
- 9.1.6. Business Performance
- 9.1.7. Key Strategic Moves and Developments
9.2. SPI Pharma, Inc.
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Operating Business Segments
- 9.2.5. Product Portfolio
- 9.2.6. Business Performance
- 9.2.7. Key Strategic Moves and Developments
9.3. Bioveta AS
- 9.3.1. Company Overview
- 9.3.2. Key Executives
- 9.3.3. Company Snapshot
- 9.3.4. Operating Business Segments
- 9.3.5. Product Portfolio
- 9.3.6. Business Performance
- 9.3.7. Key Strategic Moves and Developments
9.4. Croda Internation PLC
- 9.4.1. Company Overview
- 9.4.2. Key Executives
- 9.4.3. Company Snapshot
- 9.4.4. Operating Business Segments
- 9.4.5. Product Portfolio
- 9.4.6. Business Performance
- 9.4.7. Key Strategic Moves and Developments
9.5. Merck And Co., Inc.
- 9.5.1. Company Overview
- 9.5.2. Key Executives
- 9.5.3. Company Snapshot
- 9.5.4. Operating Business Segments
- 9.5.5. Product Portfolio
- 9.5.6. Business Performance
- 9.5.7. Key Strategic Moves and Developments
9.6. MVP Laboratories
- 9.6.1. Company Overview
- 9.6.2. Key Executives
- 9.6.3. Company Snapshot
- 9.6.4. Operating Business Segments
- 9.6.5. Product Portfolio
- 9.6.6. Business Performance
- 9.6.7. Key Strategic Moves and Developments
9.7. OZ Biosciences
- 9.7.1. Company Overview
- 9.7.2. Key Executives
- 9.7.3. Company Snapshot
- 9.7.4. Operating Business Segments
- 9.7.5. Product Portfolio
- 9.7.6. Business Performance
- 9.7.7. Key Strategic Moves and Developments
9.8. InvivoGen Corporation.
- 9.8.1. Company Overview
- 9.8.2. Key Executives
- 9.8.3. Company Snapshot
- 9.8.4. Operating Business Segments
- 9.8.5. Product Portfolio
- 9.8.6. Business Performance
- 9.8.7. Key Strategic Moves and Developments
9.9. Evonik Industries AG
- 9.9.1. Company Overview
- 9.9.2. Key Executives
- 9.9.3. Company Snapshot
- 9.9.4. Operating Business Segments
- 9.9.5. Product Portfolio
- 9.9.6. Business Performance
- 9.9.7. Key Strategic Moves and Developments
9.10. Zoetis, Inc.
- 9.10.1. Company Overview
- 9.10.2. Key Executives
- 9.10.3. Company Snapshot
- 9.10.4. Operating Business Segments
- 9.10.5. Product Portfolio
- 9.10.6. Business Performance
- 9.10.7. Key Strategic Moves and Developments